Abstract
In the past ten years, there has been a revolution in our ability to generate human pluripotent stem cells (hiPSCs) from adult somatic cells. hiPSCs can be differentiated into many cell types, including cardiomyocytes (hiPSC-CMs), providing cardiovascular scientists for the first time with a human heart muscle cell line. hiPSC-CMs have several potential uses: to study mechanisms of disease, as a platform for screening drugs for efficacy and toxicity, and as cell therapy for diseases such as cardiomyopathy. In this review, we discuss the potential of using hiPSC-CMs for drug toxicity testing, and in particular to screen genetic variants found to be predictive of which patients develop cardiotoxicity after receiving the chemotherapeutic agent doxorubicin.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 23-27 |
| Number of pages | 5 |
| Journal | Progress in Pediatric cardiology |
| Volume | 37 |
| Issue number | 1-2 |
| DOIs | |
| State | Published - Dec 1 2014 |
Funding
This work was supported in part by a grant from the NIH ( HL11708301 ) and from the Children's Cardiomyopathy Foundation to Dr. Bernstein and by an American Heart Association Beginning Grant-in-Aid ( 14BGIA20480329 ) and NIH Pathway to Independence Award ( K99 HL121177 ) to Dr. Burridge.
Keywords
- Cancer
- Cardiomyocytes
- Doxorubicin cardiotoxicity
- ROS
- Stem cells
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Cardiology and Cardiovascular Medicine
